Streetbeat News

Products Services

KULR

KULR Technology Group, Inc. (NYSE:KULR) has announced a partnership with a leading global space innovator to design, develop, and deliver battery systems for space missions scheduled for 2024 and beyond. These batteries will support the growing commercial space business, with KULR's proprietary battery safety and performance technologies playing a crucial role. The partnership anticipates follow-on orders that could significantly increase the frequency and scale of planned space missions. KULR's expertise in rapid battery development and in-house production is expected to decrease time to flight readiness, positioning KULR as a key player in powering the next frontier of space exploration.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:34 pm

DYAI

Dyadic International, Inc. has progressed its collaboration with the Israel Institute for Biological Research, focusing on developing solutions for bio-threats and emerging diseases. This partnership aims to leverage Dyadic's proprietary C1 gene expression platform to accelerate the development and production of biopharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:33 pm

PANW

SEED

SOGP

Palo Alto Networks' shares dropped 24% due to Q3 guidance below estimates. Origin Agritech's revenue surged 77% YOY, netting $8.7M, leading to a 129% stock increase. Sound Group's stock soared 174% after announcing new AI-powered applications.

Portfolio Pulse from ryanfaloona@benzinga.com

February 21, 2024 | 1:32 pm

COYA

Coya Therapeutics is expanding its COYA 302 product into Alzheimer's Disease, leveraging its proprietary low-dose interleukin-2 formulation and CTLA4-Ig combination. This expansion follows partnerships and planned IND filings for ALS, FTD, and PD, with a double-blind trial for LD IL-2 in AD ongoing. The company highlights its 'Pipeline in a Product' approach, aiming to address neurodegenerative diseases' complex immune pathways. With a two-year cash runway and anticipated milestones in 2024, Coya aims to deliver therapies for neurodegenerative diseases affecting millions in the U.S.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:32 pm

CHRS

Coherus BioSciences has launched UDENYCA ONBODY, a device for delivering pegfilgrastim-cbqv in just five minutes. The device features a unique, automatic, retractable needle mechanism designed to enhance safety and comfort for cancer patients.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:31 pm

AMRC

Ameresco, Inc. (NYSE:AMRC) has been awarded by Hawaiian Electric Company to develop the 'Ūkiu Energy 40MW renewable energy site in Maui, enhancing grid reliability and advancing Hawaii's clean energy goals. The facility, featuring a biofuel-powered generator with six dual-fuel engines, will support decarbonization, reduce Maui's fossil fuel dependence, and provide 24/7 renewable energy. This project, pending Public Utilities Commission approval, is part of Hawaiian Electric's clean energy procurement phase and will be built, owned, and operated by Ameresco. It marks Ameresco's fourth award with Hawaiian Electric, following the Kūpono Solar, Pu`uloa Energy, and Pu`uloa Solar projects.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:30 pm

CRL

Charles River Laboratories International, Inc. (CRL) and Wheeler Bio have announced a strategic agreement to provide early-stage biotech companies with a streamlined path from discovery to first-in-human clinical trials. This partnership combines Charles River's expertise in antibody discovery, safety, and analytics with Wheeler Bio's Portable CMC platform, aiming to accelerate therapeutic discovery to IND submission timelines and reduce the complexity of managing multiple vendor relationships.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:28 pm

IPX

PCT

As of Feb. 21, 2024, PureCycle Technologies, Inc. (PCT) and IperionX Limited (IPX) in the materials sector are considered overbought with RSI values of 70.28 and 72.51, respectively. PCT recently reported a production update, leading to a 32% stock increase over five days, while IPX is advancing in titanium production, with its stock up 38% over the past month.

Portfolio Pulse from Avi Kapoor

February 21, 2024 | 1:26 pm

ABOS

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) announced its plans to present data from the Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's treatment at the AD/PD 2024 meeting. The study showed sabirnetug to be well-tolerated with a favorable safety profile and significant amyloid plaque reduction. Acumen is set to initiate a Phase 2 trial in the first half of 2024, highlighting sabirnetug's potential as a next-generation treatment for early Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:24 pm

TALK

Talkspace, a leader in online therapy, has partnered with Wheel, a health tech company, to enhance its virtual care offerings. This collaboration aims to expand Talkspace's capabilities in providing accessible mental health services.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 1:22 pm